home All News open_in_new Full Article

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations No dose reductions required to the standard-of-care VEN/AZA with TUS dose cohorts TUS+VEN+AZA triplet continues to […]


today 8 d. ago attach_file Other

attach_file Events
attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Society
attach_file Politics
attach_file Other
attach_file Science
attach_file Science
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Events
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Transport


ID: 1544051049
Add Watch Country

arrow_drop_down